Related references
Note: Only part of the references are listed.Excess Early Mortality in Schizophrenia
Thomas Munk Laursen et al.
ANNUAL REVIEW OF CLINICAL PSYCHOLOGY, VOL 10 (2014)
Prescription Patterns of Psychotropic Medications for the Treatment of Psychotic Disorders in the Largest Mental Health Institutions of Uganda
Annika Rukat et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2014)
Schizophrenia: an integrated sociodevelopmental-cognitive model
Oliver D. Howes et al.
LANCET (2014)
Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia
Magdolna Tardy et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
Chlorpromazine versus placebo for schizophrenia
Clive E. Adams et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
Stefan Leucht et al.
LANCET (2013)
Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010
Harvey A. Whiteford et al.
LANCET (2013)
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010
Joshua A. Salomon et al.
LANCET (2012)
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
Christopher J. L. Murray et al.
LANCET (2012)
Cost effectiveness of strategies to combat neuropsychiatric conditions in sub-Saharan Africa and South East Asia: mathematical modelling study
Dan Chisholm et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study
Marc De Hert et al.
SCHIZOPHRENIA RESEARCH (2010)
Schizophrenia in Thailand: prevalence and burden of disease
Pudtan Phanthunane et al.
POPULATION HEALTH METRICS (2010)
11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)
Jari Tiihonen et al.
LANCET (2009)
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Stefan Leucht et al.
LANCET (2009)
The incidence of diabetes in atypical antipsychotic users differs according to agent-results from a multisite epidemiologic study
Marianne Ulcickas Yood et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)
Schizophrenia treatment in the developing world:: an interregional and multinational cost-effectiveness analysis
Dan Chisholm et al.
BULLETIN OF THE WORLD HEALTH ORGANIZATION (2008)
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder:: an open randomised clinical trial
Rene S. Kahn et al.
LANCET (2008)
The burden of schizophrenia on caregivers - A review
A. George Awad et al.
PHARMACOECONOMICS (2008)
A systematic review of mortality in schizophrenia - Is the differential mortality gap worsening over time?
Sukanta Saha et al.
ARCHIVES OF GENERAL PSYCHIATRY (2007)
Olanzapine versus chlorpromazine in the treatment of schizophrenia - A pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa
Martin Dossenbach et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2007)
Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder:: observational follow-up study
Jari Tiihonen et al.
BRITISH MEDICAL JOURNAL (2006)
The economic burden of schizophrenia in Canada in 2004
R Goeree et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
JA Lieberman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol:: 12-Month follow-up of the intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study
M Dossenbach et al.
JOURNAL OF CLINICAL PSYCHIATRY (2005)
Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores
LA Lenert et al.
SCHIZOPHRENIA RESEARCH (2004)
Relationship of atypical antipsychotics with development of diabetes mellitus
LL Citrome et al.
ANNALS OF PHARMACOTHERAPY (2003)
Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis
JF Rushby et al.
HEALTH POLICY AND PLANNING (2001)
Share Paper
